pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
mRNA Therapeutic · news · pharmadog
← back to mRNA Therapeutic
News · mRNA Therapeutic
232
stories
10h
nChroma halves workforce, BioXcel lets execs go
biospace
1d
Merck scraps centerpiece of $2.7B ArQule buy after late-stage safety concerns
biospace
1d
Pfizer enters in vivo CAR-T space via 3-program, $2.6B deal with China’s Starna
fiercebiotech
2d
Scientists uncover ‘very detailed map’ of an enzyme target for rare metabolic disease
fiercebiotech
6d
The future of heart drug research in the wake of study setbacks
stat
12d
Could we see 10 Chinese Big Pharmas within a decade? Some CEOs think so
fiercebiotech
13d
Democrats’ midterm victory, and a questionable fertility procedure
stat
13d
Moderna enjoys stable vaccine sales thanks to global COVID uptake
biospace
13d
Forge’s Piteri-Molina on AI, Ohio and what’s next for gene therapy manufacturing
biospace
13d
Merck, Moderna serve 99% of trial patients with mRNA vaccine as personalized shots near market
biospace
13d
Moderna’s norovirus vaccine plans in limbo in wake of phase 3 miss
fiercebiotech
15d
How a Ms. Frizzle-esque librarian helped Flagship’s Louisa Helms find biotech
biospace
20d
Assessing Merck and Moderna’s mRNA cancer vaccine
stat
21d
Merck looks ahead to ‘another year of investment’ as Keytruda cliff looms
biospace
21d
Merck outlines 2027 as ‘another year of investment’ despite recent clinical wins
fiercebiotech
23d
Novartis faces $1.9B hit from Avidity fail but maintains confidence in $12B buy
biospace
23d
Opinion: Cancer vaccines are finally here. How do we get them to patients?
stat
24d
BioNTech, DualityBio say ADC had ‘modest’ benefit in breast cancer study
biopharma dive
24d
ESMO 2026: Analysts warm to Merck, Moderna’s cancer vaccine after frustrating data leak
biospace
24d
STAT+: Five biotech updates to read after ESMO this weekend
stat
24d
BioNTech sees ‘limited’ benefit to ADC after phase 3 reveals modest efficacy, ILD cases
fiercebiotech
24d
STAT+: Moderna CEO on what’s next after success in cancer vaccine
stat
24d
Australia's clinical trial advantage gains ground amid U.S. uncertainty
biospace
25d
STAT+: After a cancer vaccine’s first success, the race is on to expand the impact
stat
26d
‘It is what it is’: Merck exec unruffled by ‘unfortunate’ leak of ESMO cancer vaccine data
fiercebiotech
27d
STAT+: Highly anticipated Moderna-Merck melanoma cancer vaccine data arrived early
stat
27d
Alnylam plans pivotal trial as Huntington’s drug notches ‘best-in-class knockdown’
biospace
27d
STAT+: Pharmalittle: We’re reading about a cancer vaccine, an experimental pancreatic cancer drug, and more
stat
28d
ESMO 2026: Merck, Moderna shares fall as cancer vaccine disappoints after data leak
biospace
28d
Moderna, Merck shares fall on eagerly anticipated cancer vaccine results
biopharma dive
← prev
page 1 of 8
next →